Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population

Vaccine

Volumn 32, Issue 44, 2014, Pages 5816-5823

  Atsmon, Jacob ^a   Caraco, Yoseph ^b   Ziv Sefer, Sagit ^c   Shaikevich, Dimitry ^a   Abramov, Ester ^c   Volokhov, Inna ^a   Bruzil, Svetlana ^c   Haima, Kirsten Y ^a,b,c   Gottlieb, Tanya ^c   Ben Yedidia, Tamar ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BIONDVAX PHARMACEUTICALS LTD   (Israel)

Author keywords

CMI; Elderly; HAI; Influenza; Multimeric 001; Prime boost; Universal

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CELLULAR IMMUNITY; CONTROLLED STUDY; COUGHING; DEPRESSED BLOOD PRESSURE; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GERIATRIC PATIENT; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; NECK PAIN; NOSE OBSTRUCTION; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SEASONAL INFLUENZA; SEROCONVERSION; SORE THROAT; VACCINATION; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; T LYMPHOCYTE; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; T-LYMPHOCYTES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84908080093     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.031     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention (CDC). Estimated influenza illnesses and hospitalizations averted by influenza vaccination-United States, 2012-2013 influenza season. Morbidity and Mortality Weekly Report 2013;62(49):997-1000.
2. Aspinall R., Del Giudice G., Effros R.B., Grubeck-Loebenstein B., Sambhara S. Challenges for vaccination in the elderly. Immun. Ageing 2007, 4:9.
3. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 2008, 46:1078-1084.
4. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
5. Lambert1 N.D., Ovsyannikova1 I.G., Pankratz V.S., Jacobson R.M., Poland G.A. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev. Vaccin. 2012, 11:985-994.
6. Sasaki S., Sullivan M., Narvaez C.F., Holmes T.H., Furman D., Zheng N., et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Investig. 2011, 121:3109-3119.
7. Govaert T.M., Sprenger M.J., Dinant G.J., Aretz K., Masurel N., Knottnerus J.A. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994, 12:1185-1189.
8. Bernstein E., Kaye D., Abrutyn E., Gross P., Dorfman M., Murasko D.M. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999, 17:82-94.
9. Brydak L.B., Machała M., Myśliwska J., Myśliwski A., Trzonkowski P. Immune response to influenza vaccination in an elderly population. J. Clin. Immunol. 2003, 23:214-222.
10. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. 2003, 115:63-73.
11. Ridenhour B.J., Campitelli M.A., Kwong J.C., Rosella L.C., Armstrong B.G., Mangtani P., et al. Effectiveness of inactivated influenza vaccines in preventing influenza-associated deaths and hospitalizations among Ontario residents aged ≥65 years: estimates with generalized linear models accounting for healthy vaccinee effects. PLoS One 2013, 8:e76318.
12. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005, 23:946-950.
13. Mannino S., Villa M., Apolone G., Weiss N.S., Groth N., Aquino I., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am. J. Epidemiol. 2012, 176:527-533.
14. Rümke H.C., Richardus J.H., Rombo L., Pauksens K., Plaßmann G., Christelle Durand C., et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modeling immunogenicity from a randomized trial. BMC Infect. Dis. 2013, 13:348-363.
15. DiazGranados C.A., Dunning A.J., Jordanov E., Landolfi V., Denis M., Talbot H.K. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013, 31:861-866.
16. Chi R.C., Rock M.T., Neuzil K.M. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin. Infect. Dis. 2010, 50:1331-1338.
17. Targonski P.V., Poland G.A. Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly. Drugs Aging 2004, 21:349-359.
18. Liu W.M., van der Zeijst B.A., Boog C.J., Soethout E.C. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum. Vaccines 2011, (7):S94-S98.
19. Parodi V., de Florentiis D., Martini M., Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011, 28:93-106.
20. Van Buynder P.G., Konrad S., Van Buynder J.L., Brodkin E., Krajden M., Ramler G., et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013, 31:6122-6128.
21. Ansaldi F., Canepa P., Ceravolo A., Valle L., de Florentiis D., Oomen R., et al. Intanza(®) 15mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012, 30:2908-2913.
22. Maduro Bouillet L.E., Dias M.O., Alves Dorigo N., Moura A.D., Russell B., Nosten F., et al. Long-term humoral and cellular immune responses elicited by a heterologous plasmodium vivax apical membrane antigen 1protein prime/adenovirus boost immunization protocol. Infect. Immun. 2011, 79:3642-3652.
23. Manque P.A., Tenjo F., Woehlbier U., Lara A.M., Serrano M.G., Xu P., et al. Identification and immunological characterization of three potential vaccinogens against cryptosporidium species. Clin. Vaccine Immunol. 2011, 18:1796-1802.
24. Calvo-Pinilla E., Navasa N., Anguita J., Ortego J. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 2012, 7:1-11.
25. Ledgerwood J.E., Wei C.J., Hu Z., Gordon I.J., Enama M.E., Hendel C.S., et al. VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 2011, 11:916-924.
26. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med. Res. Methodol. 2010, 10:18. http://www.biomedcentral.com/1471-2288/10/18.
27. Thomas P.G., Keating R., Hulse-Post D.J., Peter C., Doherty P.C. Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 2006, 12:48-54.
28. Ennis F.A., Meager A., Beare A.S., Qi Y.H., Riley D., Schwarz G., et al. Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 1981, 2:891-893.
29. Ben-Yedidia T. Progress towards a universal influenza vaccine. Futur. Virol. 2011, 6:237-248.
30. Atsmon J., Kate-Ilovitz E., Shaikevich D., Singer Y., Volokhov I., Haim K.Y., Ben-Yedidia T. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J. Clin. Immunol. 2012, 32:595-603.
31. Gottlieb T., Hassin S., Ben-Yedidia T. Preparedness ahead of pandemic outbreaks. BioProcess Int. 2013, 11(9).
32. WHO Manual on Animal Influenza Diagnosis and Surveillance, Geneva; 2002. http://www.who.int/csr/resources/publications/influenza/en/whocdscsrncs20025rev.pdf.
33. FDA/CBER. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials; September 2007.
34. CIDRAP publication: studies: flu vaccine effectiveness waned over 2011-12 season. By: Robert Roos. Filed under: influenza vaccines, Jan 31, 2013. http://www.cidrap.umn.edu/news-perspective/2013/01/studies-flu-vaccine-effectiveness-waned-over-2011-12-season.
35. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R.Z., Chotpitayasunondh T., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 2008, 15:1042-1053.
36. McElhaney J., Xie D., Hager W.D., Barry M.B., Wang Y., et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 2006, 176:6333-6339.
37. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012, 18:274-280.
38. Pravica V., Perrey C., Stevens A., Lee J.H., Hutchinson I.V. A Single nucleotide polymorphism in the first intron of the human IFN-γ gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ production. Hum. Immunol. 2000, 61:863-866.